Placebo orally for 12 weeks

2 trials

Sponsors

NOVARTIS BIOSCIENSES PERU S.A.,, MERCK SHARP & DOHME PERU S.R.L.,

Unknown Phase

8-WEEK, DOUBLE-BLIND, MULTICENTER, RANDOMIZED, MULTIFACTORIAL, PLACEBO-CONTROLLED PARALLEL GROUPS STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALISKIREN ADMINISTERED ONLY AND IN COMBINATION WITH HYDROCHLOROTHIAZIDE IN PATIENTS WITH ESSENTIAL HYPERTENSION

Active, not recruitingPER-065-04

NOVARTIS BIOSCIENSES PERU S.A.,

Updated: 2023-09-04

MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE SAFETY OF THE MONOTHERAPY WITH MK-0431 IN PATIENTS WITH DIABETES MELLITUS TYPE 2 AND CHRONIC RENAL INSUFICIENCY THAT HAVE AN INAPPROPRIATE GLUCEMIC CONTROL.

Active, not recruitingPER-089-04

MERCK SHARP & DOHME PERU S.R.L.,

Target: 12Updated: 2023-09-04